Sandoz Group AG Reports Strong FY 2024 Performance, Targets Continued Growth in 2025
Sandoz Group AG reported strong FY 2024 results, driven by double-digit growth in its biosimilars segment, and expects continued growth in 2025 with mid-single digit net-sales growth and improved profitability.
2 minutes to read